INTRODUCTION

The mammalian endoplasmic reticulum (ER) is a large membrane network of interconnected cisternae or sheets and tubules located throughout the cytosol (Baumann and Walz, 2001; Shibata et al., 2006; Lu et al., 2009, 2011). Protein and lipid synthesis and certain posttranslational modifications occur within its membrane-bound compartments. During mitosis, the ER architecture undergoes a major rearrangement to extended cisternae, with a very small fraction remaining organized as tubules (Lu et al., 2009, 2011). During interphase newly made secretory proteins leave the ER in COPII-based transport carriers, which bud from specialized ER exit sites (ERES) scattered throughout the ER. These carriers coalesce to form the vesicular-tubular network of the so-called ER Golgi intermediate compartment (ERGIC). Elements of the intermediate compartment that contain newly synthesized proteins are continuously transported along microtubules toward the perinuclear region, where they deliver their contents to the cis face of the Golgi apparatus. Fully processed proteins exit at the opposite end of the Golgi, the trans face, to reach the trans-Golgi network (TGN), from which they are transported to the plasma membrane and endosomes (Emr et al., 2009).

The dynamics of the Golgi apparatus, critical for all its functions, can be studied by the use of reagents that trap the Golgi in states that are usually sparsely populated or are not present in a normal cell. Cell-permeable small molecules with these properties are useful, particularly because they can be specific, fast acting, and reversible, allowing detailed study of Golgi disassembly and reassembly. In contrast, no equivalent chemicals are available to study the organization and function of the ER. By use of a phenotypic screen of inhibitors of exocytic vesicular traffic, we discovered a small molecule, dispergo (“disrupt ER and Golgi”), which we call dispergo. Using a phenotypic screen, we identify a small molecule, dispergo, that induces reversible loss of the ER cisternae and extensive ER tubulation, including formation of ER patches comprising densely packed tubules. Dispergo also prevents export from the ER to the Golgi apparatus, and this traffic block results in breakdown of the Golgi apparatus, primarily due to maintenance of the constitutive retrograde transport of its components to the ER. The effects of dispergo are reversible, since its removal allows recovery of the ER cisternae at the expense of the densely packed tubular ER patches. This recovery occurs together with reactivation of ER-to-Golgi traffic and regeneration of a functional Golgi with correct morphology. Because dispergo is the first small molecule that reversibly tubulates the ER and inhibits its export function, it will be useful in studying these complex processes.
that causes a rapid change in the architecture of the ER, involving loss of cisternae and extensive tubulation, including formation of densely packed tubules throughout the cytoplasm, rendering export from the ER nonfunctional. Lack of anterograde transport from the ER eventually causes loss of the Golgi apparatus together with retention of its contents in the ER. Removal of dispergo leads to reestablishment of the ER architecture: ER cisternae reappear, densely packed ER tubules disappear, membrane transport from the ER reactivates, and a functional Golgi apparatus reassembles.

RESULTS
Identification of dispergo as an inhibitor of VSVGβ-green fluorescent protein export from the ER
Using an image-based, high-throughput phenotypic assay that we developed previously for inhibitors of VSVGβ-green fluorescent protein (GFP) exocytic vesicular traffic (Feng et al., 2003) to screen a diversity-oriented library of 10,000 small molecules resembling the natural product carpanone, we identified a number of compounds that block VSVGβ-GFP exit from the Golgi or cause Golgi fragmentation (Goess et al., 2006). We chose to use a natural product as the core structure for the diversity-oriented synthesis because we hypothesized that such structures would have a higher intrinsic ability to bind proteins. This strategy proved to be successful, as shown by our recent discovery of secramine, a cell-permeable, galanthamine-like molecule found to be an inhibitor of vesicular traffic from the Golgi by interference with the function of the small GTPase Cdc42 (Pelish et al., 2006). We describe here a new molecule identified in the same screen, which we call dispergo (Figure 1A). It inhibits, with IC₅₀ = 6.8 μM, traffic of VSVGβ-GFP from the ER to the plasma membrane in BSC1 cells upon transfer from 40 to 32°C (Figure 1, B and C); it is also active in HeLa and Chinese hamster ovary cells (unpublished data). Carpanone (Figure 1A), which inspired the library from which dispergo was identified, is inactive (Figure 1, B and C); in its presence, as in untreated cells, VSVGβ-GFP accumulates in the ER in cells kept at 40°C and rapidly reaches the Golgi apparatus and the plasma membrane soon after transfer to 32°C.

In addition to rapidly inhibiting VSVGβ-GFP traffic to the plasma membrane, dispergo also prevented VSVGβ-GFP from reaching the Golgi apparatus marked with GalT-tomato (compare the control in Figure 2A with dispergo in Figure 2, B and C). Instead we saw the appearance of bright VSVGβ-GFP patches in cells maintained at 40°C or in cells transferred from 40 to 32°C (Figure 2, B and D); these VSVGβ-GFP patches colocalized with newly formed patches of the ER marker TRAPα (Figure 2D).

Reversible changes of the ER architecture induced by dispergo
We then followed the effect of dispergo on the distribution of another ER marker, GFP-β-Sec61β, and found the rapid accumulation of bright GFP-Sec61β patches (Figure 3A, top, arrowheads, and Supplemental Movie S2). The appearance of the ER patches coincided with extensive ER tubulation and loss of ER cisternae (Figure 3B, solid arrowheads). The effect of dispergo on the ER architecture was reversible, as demonstrated by the disappearance of the ER patches during the washout period along with the abrupt reappearance of ER cisternae (Figure 3C); eventually, the cells recovered the characteristic combination of cisternae and tubules in interphase cells. GFP-β-Sec61β within the dispergo-induced patches exchanged rapidly, presumably though direct connections between the patches and the surrounding ER, as shown by the relatively fast recovery of fluorescence signal in photobleached patches, with half-times in the range of 20–100 s (Figure 3, D and E, and Supplemental Movie S3).

The effect of dispergo on the organization of the ER also occurred in cells whose protein synthesis was acutely blocked by cycloheximide treatment (unpublished data).

These observations led us to examine in more detail the effects of dispergo on the architecture of the ER. Thin-section transmission electron microscopy of cells treated with dispergo indicate the appearance of numerous clusters containing densely packed membrane profiles ~50 nm in diameter (Figure 3F, solid arrowheads)
were often associated with additional membrane profiles, ~100 nm wide, extending toward adjacent regions within the cytosol, perhaps communicating with other clusters or with the rest of the ER (Figure 3F, enlargement, open arrowheads). We found no morphological evidence to support the presence of a limiting membrane surrounding the tubular clusters.

The patches induced by dispergo contained the ER membrane marker HA-DP1 (Supplemental Figure S1A), the endogenous ER luminal protein calreticulin (Supplemental Figure S1B), and the ER retention signal KDEL fused to GFP (ss-GFP-KDEL; Supplemental Figure S1C). The fluorescence intensities associated with calreticulin or ss-GFP-KDEL in the ER patches were significantly lower (Supplemental Figure S1, B and C, arrowheads), consistent with a lower volume-to-membrane ratio in tubules than in cisternae. Similar ER patches tracked with these markers were also observed in other cells, such as NRK, HeLa, Ptk2, and mouse MEF cells (unpublished data). We note that dispergo treatment led to efficient formation of ER patches in cells that did not express ER protein markers (Supplemental Figure S1, D, E, and F), suggesting that the patches do not correspond to the organized smooth ER associated with the stacking of smooth ER (Snapp et al., 2003) or to patches of smooth ER induced by phenyl-2-decanoyl-amino-3-morpholino-1-propanol-hydrochloride (Sprocati et al., 2006), as these ER morphologies only seem to appear upon ectopic overexpression of ER membrane proteins.

Generation and maintenance of the ER tubular network require the presence of microtubules (Terasaki et al., 1986; Waterman-Storer and Salmon, 1998; Lu et al., 2009). We found, however, that the extensive ER tubulation induced by dispergo treatment does not depend on the microtubule network. We first treated BSC1 cells with nocodazole to depolymerize microtubules, leading to loss of ER tubules and formation of ER cisternae (Figure 3G, left; Lu et al., 2009). We then followed this treatment by incubating with nocodazole and dispergo together for 3 h and found that dispergo induced formation of ER tubules and ER patches at the expense of ER cisternae, despite the continued presence of an inhibitor of microtubule dynamics (Figure 3G, right).

**Dispergo disrupts recruitment of exocytic cargo to the ERES**

Cargo export from the ER to the Golgi apparatus is mediated by vesicular carriers that form at ERES and contain Sec31a, a component of the COPII coat (Lee et al., 2004). Because dispergo inhibits the ER export of VSVG^ts-GFP (Figure 2B), we asked whether dispergo might inhibit ER export by preventing the recruitment of Sec31a to ERES. We found no statistical difference ($p = 0.40$) in the density of Sec31a-containing fluorescent spots in the absence ($0.25 \pm 0.05 \mu m^2; n = 20$ cells) or presence of dispergo ($0.21 \pm 0.07 \mu m^2; n = 15$ cells; Supplemental Figure S2A). In contrast to these results, we found that VSVG^ts-GFP failed to accumulate at ERES in cells treated with dispergo. In control cells not treated with dispergo and maintained at the nonpermissive temperature of 40°C, VSVG^ts-GFP displayed the expected homogeneous distribution throughout the ER and absence of concentration in the ERES marked with Sec31a (Figure 4A). A 10-min incubation at the permissive temperature of 32°C led to the expected concentration of VSVG^ts-GFP on the ERES and its accumulation in the perinuclear region associated with the Golgi apparatus (Figure 4B). In contrast, cells treated with dispergo at 40°C accumulated VSVG^ts-GFP in patches, which did not colocalize with Sec31a in ERES (Figure 4C). Transfer of the dispergo-treated cells from 40 to 32°C confirmed both loss of VSVG^ts-GFP export from the ER and accumulation of VSVG^ts-GFP as patches that did not colocalize with Sec31a at ERES (Figure 4D). The same results were obtained

---

**FIGURE 2:** Dispergo inhibits the traffic of VSVG^ts-GFP from the ER to the Golgi apparatus. BSC1 cells stably expressing GalT-tomato were transduced with adenovirus to express VSVG^ts-GFP overnight at 40°C. Cells were then treated with DMSO (control) or dispergo for 40 min at 40°C and subsequently shifted to 32°C for 20 min. (A) Control cells treated with DMSO only. (B–D) Cells treated with dispergo. Note in B the redistribution of VSVG^ts-GFP into patches in cells kept at 40°C during the dispergo treatment. (C) Under these experimental conditions, a significant amount of GalT-tomato colocalized with Giantin, validating the use of GalT-tomato as a Golgi marker. Endogenous Giantin was identified by immunostaining. (D) Colocalization of VSVG^ts-GFP patches with endogenous TRAPα, an ER marker (arrowheads) visualized by immunostaining in cells treated with dispergo. All images were from fixed BSC1 cells acquired using wide-field fluorescence microscopy. Scale bar, 10 μm.
with cells kept at the permissive temperature for significantly longer times (unpublished data). We also determined the exchange dynamics between cytosolic and membrane bound COPII at the ERES using fluorescence recovery after photobleaching (FRAP) analysis and found that the exchange dynamics slightly increased upon dispergo treatment (Supplemental Figure S2). This result is in agreement with earlier observations demonstrating increased dynamic recruitment of COPII to ERES sites in the absence of cargo recruitment and vesicle budding (Forster et al., 2006). These observations suggest that dispergo prevents access to ERES mainly by retaining VSVG*-GFP on ER patches.

**Dispergo induces retention of Golgi proteins in the ER and consumption of the Golgi apparatus**

Constituents of the Golgi apparatus continuously cycle between the Golgi and the ER (Storrie, 2005). The observed inhibition by dispergo of anterograde VSVG*-GFP traffic from the ER to the Golgi (Figures 1 and 2) led us to test whether dispergo also prevents ER export of Golgi components that cycle between the ER and the Golgi and to ask whether this inhibition would result in loss of the Golgi apparatus.

We examined the effects of dispergo on the localization of Golgi markers with known steady-state localizations. The following proteins marked the cis-Golgi: GPP130 (Linstedt et al., 1997), GFP-ERGIC53 (Schindler et al., 1993), KDEL receptor (Tang et al., 1993), GM130 (Nakamura et al., 1995), and β-COP (Oprins et al., 1993); Giantin marked the medial Golgi (Linstedt et al., 1995), and GalT-tomato marked the trans-Golgi. We also explored the effects of dispergo in the trans-Golgi network (TGN), as represented by Vti1a (Kreykenbohm et al., 2002), TGN38 (Luzio et al., 1990), Vamp4-GFP (Steegmaier et al., 1999), and Golgin97 (Lu et al., 2004). Dispergo treatment led to retention in the ER of all Golgi markers, except for Golgin97. The transmembrane proteins Vamp4-GFP (Figure 5A, arrowheads), GFP-ERGIC53 (Figure 5B, open arrowheads), KDEL receptor (Supplemental Figure S3A), and GalT-tomato (Figure 6A) also accumulated in the ER patches, whereas the transmembrane proteins GPP130 (Figure 5C), Giantin (Supplemental Figure S3B), Vti1a (Supplemental Figure S3C), and TGN38 (Supplemental Figure S3D) did not. The peripheral membrane protein Golgin97 (Supplemental Fig 3E) was released from the Golgi and appeared in the cytosol, whereas GM130 (Figure 5B) concentrated at the ERGIC in the vicinity of ERES labeled here with Sec31a (Figure 5B, arrowheads). Using GM130 as an “adopted ERES marker” in dispergo-treated cells, we found that β-COP relocalized to this region (Supplemental Figure S3F). In contrast to the accumulation of VSVG*-GFP in ER patches (Figure 2, B and D), the transmembrane protein GFP-ERGIC53 (Figure 5B) concentrated at the ERES and in the ER patches. We also found that rate of redistribution from the Golgi to the ER could vary significantly, as exemplified by the significant relocalization of GM130 from the perinuclear Golgi region to the ERES in cells treated with dispergo for 20 min, whereas most of VAMP4-GFP remained in the perinuclear TGN (Figure 5D) in NRK cells.

To document the temporal relationship between the retention of Golgi components in the ER and the disappearance of the Golgi apparatus mediated by dispergo, we used spinning disk confocal microscopy to acquire time-lapse series from BSC1 cells coexpressing GFP-Sec61β and GalT-tomato (Figure 6A and Supplemental Movie S4). The first detectable ER patches, which contained the ER marker GFP-Sec61β but not the Golgi marker GalT-tomato, appeared <50 min after addition of dispergo; by this time, the drug had already blocked ER export of VSVG*-GFP (see Figures 2, B and D, and 4). After further dispergo treatment, the perinuclear fluorescence signal of GalT-tomato, which marks the Golgi apparatus, became barely detectable. Quantification of these observations is shown in Figure 6B. The temporal dissociation between appearance of ER patches (marked with GFP-Sec61β) and loss of the perinuclear Golgi signal (marked with GalT-tomato) suggests that loss of the Golgi apparatus is a secondary effect due to inhibition of ER export by dispergo.

**The effects of dispergo are specific to the ER**

In contrast to effects of dispergo on ER tubulation and the block in ER export, we were unable to detect perturbations in the clathrin-mediated uptake of fluorescently labeled transferrin (Supplemental Figure S4A). The dynamics of clathrin-dependent, endocytic coated-pit formation could be monitored as accumulation of the AP2 adaptor, on which dispergo had no effect (Supplemental Figure S4B, kymographs). Dispergo also had no effect on the distributions of early (Supplemental Figure S4C) and late endosomes/lysosomes (Supplemental Figure S4D), nor did it influence the organization of the actin and tubulin cytoskeleton (Supplemental Figure S4E and F). Close interactions between tubular ER and mitochondria have been described (de Brito and Scorrano, 2010; Friedman et al., 2011); consistent with these observations, major alterations in the tubular ER organization led to mitochondrial fragmentation, as detected by MitoTracker staining in cells treated with dispergo (Supplemental Figure S4G).

**ER stress does not induce formation of ER patches**

To test whether cells subjected to ER stress might alter the ER morphology in a way similar to that observed upon dispergo treatment, we incubated BSC1 cells for 24 h with tunicamycin or dithiothreitol (DTT) and monitored the distribution of GFP-Sec61β and caerulein. As illustrated by the results shown in the images in Supplemental Figure S5, generation of an acute ER stress response by treatment with these compounds did not generate ER patches and did not change in a detectable way the overall morphology of the ER.

**DISCUSSION**

In this study, we characterize the unique effects of the small molecule dispergo on the architecture of the ER and the associated strong inhibition of ER export. A secondary effect of dispergo is consumption of the Golgi apparatus, primarily due to loss of traffic in the anterograde but not the retrograde direction between the ER and the Golgi apparatus. The morphological effects of dispergo on the organization of the ER are unrelated to the perturbations generated during acute ER stress response or to the ER patches observed upon conditions of chemical perturbation with phenyl-2-decanoyl-amino-3-morpholino-1-propanolhydrochloride and organized smooth ER generated by ectopic overexpression of ER membrane proteins (Snapp et al., 2003; Sprocati et al., 2006). These effects are reversible and do not appear to affect endocytosis, the organization of the endosomal and lysosomal compartments, or the actin and microtubule cytoskeletons. A recent study, independently conducted by one of us, uncovered similar effects on the organization and function of the ER in cells treated with apogossypol (Varadarajan et al., 2012).

The relatively fast onset of the perturbations induced by dispergo (17 ± 3 min; Figure 6B) suggests that it does not involve de novo synthesis of proteins, a conclusion we confirmed by observing the same effects of dispergo in cells whose protein synthesis was prevented by simultaneous treatment with cycloheximide (unpublished data).

We do not yet know how dispergo drives the transformation of ER cisternae into tubules. Although in vivo generation of ER tubules requires direct contact with microtubules, we can rule out an activation
FIGURE 3: Effect of dispergo on the dynamics and morphology of the ER. (A) The effects of dispergo are reversible. Two-dimensional time-lapse series of BSC1 cells stably expressing GFP-Sec61β treated with dispergo for 1 h, showing the gradual appearance of ER patches (top, solid arrowheads; see Supplemental Movie S1). After a further 2-h incubation with dispergo, the compound was removed (bottom). The time-lapse series shows the gradual disappearance of the ER patches (bottom, open arrowheads; see Supplemental Movie S2). (B, C) Two-dimensional time-lapse series from BSC1 cells expressing mRFP1-Sec61β (B) or GFP-Sec61β (C). The images in B highlight the disappearance of ER cisternae (arrowheads) and appearance of ER patches upon dispergo treatment. The images in C are from an enlarged...
The acute ER tubulation induced by dispergo results in the accumulation of ER patches containing a large amount of condensed tubules. This architectural perturbation correlates with a dramatic interference of ER export, to the extent that the contents of the Golgi apparatus are eventually lost, presumably by retention of Golgi constituents in the ER as they traffic constitutively from the Golgi apparatus to the ER. The redistribution of Golgi constituents back to the ER is fundamentally different from that induced by other small molecules such as brefeldin A (Klaunser et al., 1992; Supplemental Figure S5D), Exo1 (Feng et al., 2003), or Exo2 (Feng et al., 2004), compounds known to activate a massive tubulation of Golgi membranes and fusion to the ER that correlates with a strong inhibition of ER exit without a detectable change in the organization of the ER. We also do not know why dispergo blocks ER export. One simple explanation is that the extensive ER tubulation induced by dispergo increases membrane tension to such an extent that formation of vesicular carriers is impaired. Protein movement along the dispergo-induced tubules does not seem to be impaired, but certain proteins do accumulate in the tubular ER patches. It is therefore possible that one or more key protein components required for ER exit are mislocalized, thereby impairing the process of carrier formation. Dispergo does not alter the distribution or peripheral density of ERES, although it slightly increases the exchange dynamics of COPII at the ERES sites. Another explanation could be that dispergo affects the lipid homeostasis in the ER, resulting in changes in its shape and function.

The effects of dispergo are reversible, since its removal allows recovery of the ER cisternae at the expense of the densely packed tubular ER patches together with reactivation of ER-to-Golgi traffic, leading to recovery of a functional Golgi with correct morphology. The properties of dispergo and the reversibility of its effects provide new opportunities to study the dynamics and function of the ER. Dispergo will be useful in identifying the molecules and interactions that guide these complex processes.

MATERIALS AND METHODS

Chemical synthesis of dispergo

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.

**General procedures.** All solid-phase reactions were performed in Poly-Prep Chromatography Columns (Bio-Rad, Hercules, CA) with agitation provided by a Lab-Line 3-D Rotator. After a reaction, the resin was washed in a standard manner: methylene chloride, then tetrahydrofuran, then 2:1 tetrahydrofuran:acetonitrile, and then methanol (4:1 acetonitrile:water). The resin was then placed on a gravity column and washed with MeOH. The resin was dried under a stream of nitrogen at room temperature. In many cases, the resin was washed again with tetrahydrofuran (2:1 with water) and then methanol (4:1 with water) prior to the next step. Then the resin was resuspended in tetrahydrofuran and reacted with the next set of reagents. Resin was usually washed and dried following the last reaction before the resin was stored for future use.
performed under house vacuum. Cleavage of resin was performed by swelling the resin in tetrahydrofuran (1 ml per 10 mg of resin), followed by addition of HF-pyridine (200 μl per 10 mg of resin), agitation for 1 h, treatment with methoxymethylsilane (1 ml per 10 mg of resin), agitation for 1 h, and filtration. Flash chromatography was performed as described previously (Still et al., 1978) or by using an HPLC Biotage system (Biotage, Uppsala, Sweden) with pre-packed FLASH silica gel columns.

**Preparation of dispergo.** Cyclopentanethiol (428 μl, 4.0 mmol), 2,6-lutidine (465 μl, 4.0 mmol), and n-butyl lithium (2.5 M in hexane, 192 μl, 4.0 mmol) were added to a mixture of resin loaded with carpanone-like core (Goess et al., 2006), and the resulting mixture was agitated for 24 h. The resin was then subjected to the standard wash and dry procedure outlined in General procedures. To the resulting resin was added a premixed solution of O-t-butylhydroxylamine (804 mg, 6.4 mmol), pyridine (776 μl, 9.6 mmol), and a 1:4 mixture of methanol:methylene chloride (20 ml), and the resulting mixture was agitated for 20 h. The resin was then subjected to the standard wash and dry procedure. To the resulting resin (50 mg, 0.04 mmol) was added tetrahydrofuran (5 ml), followed by HF-pyridine (2 ml), and the resulting mixture was agitated for 2 h. Methoxymethylsilane (10 ml) was then added, and the resulting mixture was agitated for 45 min. The mixture was then filtered and washed with methylene chloride, and the combined filtrates were concentrated and the remaining volatiles evaporated under high vacuum. Column chromatography (0:100–4:96 methanol:methylene chloride) afforded 10 mg (54%, three steps) of dispergo. Dispergo was isolated as a 4:1 (E/Z) mixture of geometrical isomers. 1H nuclear magnetic resonance (NMR; 400 MHz, CDC13): δ 6.91 (s, 1H), 6.58–6.72 (m, 3H), 6.26–6.36 (m, 1H), 6.13 (bs, 1H), 5.98–6.10 (m, 1H), 5.56–5.64 (m, 1H), 5.36–5.42 (m, 1H), 5.22–5.34 (m, 1H), 4.96–5.04 (m, 1H), 4.86–4.96 (m, 1H), 4.40–4.54 (m, 3H), 3.88–4.12 (m, 3H), 3.76 (bs, 1H), 3.58–3.76 (m, 4H), 3.47 (t, J = 6.0 Hz, 3H), 3.20–3.36 (m, 3H), 2.90–3.04 (m, 2H), 2.65 (dd, J = 14.2, 2.2 Hz, 1H), 2.38 (bs, 1H), 1.05–2.05 (m, 20H), 0.80–1.02 (m, 2H), 0.66–0.80 (m, 2H). 13C NMR (100 MHz, CDC13): δ 152.81, 152.76, 152.62, 150.5, 149.5, 145.5, 138.1, 134.4, 133.7, 131.6, 127.34, 127.28, 126.9, 122.1, 117.9, 117.6, 116.4, 114.9, 114.8, 113.5, 100.6, 100.2, 78.4, 69.9, 63.1, 62.4, 62.3, 61.7, 61.6, 45.6, 44.3, 42.6, 41.4, 39.8, 39.6, 37.0, 36.7, 35.12, 35.07, 35.0, 34.7, 34.6, 34.4, 34.1, 33.8, 33.5, 33.4, 33.11, 33.06, 32.9, 32.8, 28.0, 27.7, 26.9, 25.1, 24.9, 24.6, 24.57, 24.3, 24.2, IR (neat, cm−1): 3367, 2929, 1624, 1492, 1422, 1196, 1132, 1076; LRMS (ES+): 668 (M+H+); HRMS (ES+): calculated for C39H37NO5S, 667.3907; found, 668.3995.

**Reagents and antibodies**

Nocodazole was from Sigma-Aldrich (St. Louis, MO). Rhodamine–phalloidin and transferrin–Alexa Fluor 488 were from Invitrogen (Carlsbad, CA). Mouse monoclonal antibody against GM130 was from Becton Dickinson (Franklin Lakes, NJ). Rabbit polyclonal antibodies against calreticulin and Giantin were from Abcam (Cambridge, MA). Rabbit polyclonal antibodies against β-COP was from EMD Chemicals (San Diego, CA). Hybridoma clone 8g5, in ER patches. (D) Golgi markers had different kinetics of relocation upon dispergo treatment. NRK cells stably expressing Vamp4-GFP without or with dispergo treatment for 20 min were processed for immunofluorescence labeling of GM130. This example highlights that the redistribution of Golgi markers to the ER can occur at different rates (in this case GM130 was faster than Vamp4-GFP). All images were acquired by a wide-field microscope. Scale bars, 10 μm.
CD63 and Lamp1 were obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). Rabbit polyclonal antibodies against Sec31a and Golgin97 were from W. Hong (Institute of Molecular and Cell Biology, Singapore). Rabbit polyclonal antibody against TRAPα was from T. Rapaport (Harvard Medical School, Boston, MA). Rabbit polyclonal and mouse monoclonal antibodies against GPP130 were from A. Linstedt (Carnegie Mellon University, Pittsburgh, PA). Goat anti-mouse and rabbit secondary antibodies conjugated with either Alexa Fluor 488 or 594 were purchased from Invitrogen.

DNA plasmids

To clone GalT-tomato, an insert containing the coding sequence of amino acids 1–81 of β-galactosyltransferase (GalT) was released by digesting pEYFP-Golgi plasmid (Takara Bio, Shiga, Japan) using NheI/BamHI and subsequently ligated into NheI/BamHI-digested ptdTomato-N1 vector (Takara Bio) to make plasmid GalT-tomato. Plasmids Sec61β in pAcGFP1-C1 (Takara Bio), HA-DP1 in pcDNA3, and Sec61β-mRFP1 were from T. Rapaport. Plasmid ERGIC53-GFP was from H.-P. Hauri (University of Basel, Basel, Switzerland). Plasmid expressing GFP-α-tubulin was from Takara Bio.

Cell culture, transfection, and stable cell lines

BSC1 and HeLa cells were obtained from the American Tissue Culture Collection. Cells were cultured at 37°C in DMEM supplemented with 10% fetal bovine serum. The transfection experiments were performed using FuGENE 6 transfection reagent (Roche, Basel, Switzerland) according to the manual.

To generate cell lines stably expressing GalT-tomato or GFP-Sec61β, BSC1 cells were transfected with either GalT-tomato or GFP-Sec61β. Pooled stable cells were selected in medium containing 0.5 mg/ml G418 (Invitrogen) and subsequently replated at very low density to obtain single colonies of cells. Colonies were screened by fluorescence microscopy, isolated, and subsequently expanded.

NRK (normal rat kidney) cells stably expressing Vamp4-GFP (Tran et al., 2007) were from W. Hong. All stable cell lines were maintained in medium supplemented with 0.1 mg/ml G418.

Dispergo, nocodazole, brefeldin A, tunicamycin, and DTT treatments

Dispergo was dissolved in dimethyl sulfoxide (DMSO) to make a 10 mM stock solution and stored at −20°C. The stock solution was directly diluted in culture medium to a final working concentration of 20 μM. DMSO, 0.2%, was used as control in parallel with dispergo treatments. Nocodazole was dissolved in DMSO at a concentration of 33 mM and stored at −20°C. The final working concentration of nocodazole was 16.5 μM dissolved in culture medium. Brefeldin A and tunicamycin were also dissolved in DMSO as 10 mM stock solutions, which were then directly diluted in culture medium to a final working concentration of 10 μM. DTT was dissolved in water to make a 100 mM stock, and the final working concentration of 100 μM was achieved by directly diluting the stock in culture medium.

Immunostaining

Cells grown on round glass coverslips were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min at room temperature. Paraformaldehyde was subsequently blocked by incubation with 100 mM NH4Cl. After extensive washes with PBS, cells were simultaneously permeabilized and stained with the required antibodies diluted in PBS containing 0.1% saponin, 5% fetal bovine serum, and 2% bovine serum albumin. Coverslips were mounted in Mowiol and sealed with nail polish.

FIGURE 6: Relocalization of the Golgi marker GalT-tomato to the ER induced by dispergo. (A) BSC1 cell transiently expressing GalT-tomato and GFP-Sec61β were treated with dispergo and imaged by spinning disk confocal microscopy (see Supplemental Movie S4). Arrowheads highlight colocalization of GalT-tomato and GFP-Sec61β at ER patches marked by GFP-Sec61β. Scale bar, 10 μm. (B) Time dependence for the loss of GalT-tomato from the perinuclear region corresponding to the Golgi apparatus induced by dispergo in BSC1 cells stably expressing GalT-tomato. The fluorescence intensity of GalT-tomato at the perinuclear region determined before dispergo addition was used to normalize the data. Plot shows mean values and SD for each time point (n = 13 cells). Golgi t1/2 represents the mean time ± SD that it took for the signal of GalT-tomato to be reduced by 50%. “ER patches onset” marks the time at which the appearance of ER patches labeled with GFP-Sec61β was first detected (n = 10 cells).

which secretes mouse monoclonal antibody against VSVG extracellular domain, was obtained from the American Type Culture Collection (Rockville, MD). Mouse monoclonal antibodies against
ACKNOWLEDGMENTS

We thank M. Ericsson for help with electron microscopy and E. Marino for maintaining the imaging resources in the Kirchhausen laboratory, and Yoshiki Tanaka for assistance with the nuclear magnetic resonance, infrared, and high-resolution mass spectrometry characterization of dispargo. R.H. was a recipient of postdoctoral fellowships from the Canadian Institutes of Health Research and National Sciences and Engineering Research Council of Canada. B.G. was a recipient of a doctoral fellowship from the U.S. Department of Defense (National Defense Science and Engineering Graduate Fellowship). This work was supported in part by National Institutes of Health Grant GM-075252 (to T.K.) and US4 AI057159 (New England Regional Center of Excellence in Biodiscretion and Emerging Infectious Disease, Core Imaging Facility, Boston, MA, as well as P01 GM62556 (to T.K. and M.S.) and SBS SUG M58080013 (to L.L.).

REFERENCES


Linstedt AD, Foguet M, Renz M, Seelig HS, Crocken J, Hauri HP (1999). A C-terminally-anchored Golgi protein is inserted into the endoplasmic reticulum and then transported to the Golgi apparatus. Proc Natl Acad Sci USA 92, 5102–5105.


